SVMPharma Real World Evidence - RWE in submissions to NICE grew 6% in 2016. RWE has found it’s place, but what next? For more information and resources visit us at www.svmpharma.com

1. RWE in submissions to NICE grow 6% in 2016
RWE has found it’s place, but what next?
SVMPharma RWE projects are built
on the strengths of:
• Knowing the RWE landscape
• Establishing connections with
healthcare professionals and key
opinion leaders
• Intelligent use of technology
RWE in submissions to NICE grew 6% in 2016
RWE has found it’s place, but what next?
For more on RWE visit:
www.svmpharma.com
1. Key to Market Access: Making the
most out of Real World Evidence
2. NICE and the NHS are changing the
way they look at cost-effective and
innovative drugs in the UK
3. Speeding up approval with RWE:
Accelerated Approval and Access
programs
RWE messages that you
may have missed out on
(Click on the links below to find out more)

2. RWE: the emerging landscape
SVMPharma RWE is built on the
strength of understanding the RWE
landscape.
In 2016, of 56 NICE published
technology assessments, around
42% utilized some form of RWE, up
from 36% in 2015. This growth
demonstrates how RWE looks set to
continue expanding throughout
2017.
However, it isn’t just the number of
RWE studies and NICE submissions
that indicates growth in RWE; new
initiatives illustrate how RWE has
become ‘part of the mindset’ in
R&D and healthcare economics
over recent years.
As well as supporting HTA
submissions, RWE is increasingly
driving faster access to drugs:
• The 2016 reforms to cancer drugs
fund highlight growing
opportunities for RWE.
• January 2017 saw NICE announce
involvement in ROADMAP, an EU
project in accordance with the
Innovative Medicines Initiative
(IMI) to share RWE in
development of AD drugs.
• With the end of EMA’s pilot in
August 2016, saw the final report
conclude “the benefit of adaptive
pathways lies…in exploring the full
potential of utilising the real
world evidence generated in
clinical practice to refine
regulators’ and other
stakeholders’ decisions.”
The increase in RWE studies over the last year and the growth and
introduction of initiatives around RWE highlight how it’s not just becoming
commonly used to support HTA, but already entering wider research
processes. In turn, this will improve RWE discussion, standards and uptake
which makes the coming years an exciting time for RWE.
RWE in submissions to NICE grew 6% in 2016
RWE has found it’s place, but what next?

3. CONTACT SVMPHARMA
Vaneet Nayar
Director SVMPharma
enquiry@svmpharma.com
Tel: +44 (0) 1252 417030
SVMPharma Ltd
Visit svmpharma.com
Follow @svmpharma
Follow on Google+
Connect via LinkedIn
Get In Touch